In the APP/PS1-21 mouse model of AD, blocking TRPA1 normalized astrocyte activity, avoided peri-synaptic astrocytic process regression, prevented neuronal dysfunction, and maintained structural synaptic integrity (Paumier et al. 2022). Here, TRPA1 is linked to Alzheimer disease.